Point72 Asset Management L.P. Has $3.64 Million Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Point72 Asset Management L.P. lifted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 91.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 212,326 shares of the biotechnology company's stock after buying an additional 101,315 shares during the period. Point72 Asset Management L.P. owned about 0.09% of ADMA Biologics worth $3,641,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. ProShare Advisors LLC raised its holdings in shares of ADMA Biologics by 30.2% in the 4th quarter. ProShare Advisors LLC now owns 79,286 shares of the biotechnology company's stock worth $1,360,000 after buying an additional 18,375 shares in the last quarter. Man Group plc grew its position in ADMA Biologics by 305.5% during the 4th quarter. Man Group plc now owns 745,300 shares of the biotechnology company's stock worth $12,782,000 after acquiring an additional 561,507 shares during the last quarter. Miura Global Management LLC grew its position in ADMA Biologics by 25.0% during the 4th quarter. Miura Global Management LLC now owns 50,000 shares of the biotechnology company's stock worth $858,000 after acquiring an additional 10,000 shares during the last quarter. Morse Asset Management Inc grew its position in ADMA Biologics by 3,144.4% during the 4th quarter. Morse Asset Management Inc now owns 7,300 shares of the biotechnology company's stock worth $125,000 after acquiring an additional 7,075 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in ADMA Biologics by 7.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 148,638 shares of the biotechnology company's stock worth $2,556,000 after acquiring an additional 10,047 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ADMA. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th. Raymond James increased their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $24.25.

ADMA Biologics Trading Up 1.3%

Shares of NASDAQ ADMA traded up $0.26 during midday trading on Friday, hitting $20.42. The stock had a trading volume of 1,316,575 shares, compared to its average volume of 3,696,807. The company's 50-day simple moving average is $20.64 and its 200 day simple moving average is $18.91. The firm has a market cap of $4.87 billion, a P/E ratio of 72.93 and a beta of 0.57. ADMA Biologics, Inc. has a fifty-two week low of $9.35 and a fifty-two week high of $25.67. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The firm had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm's quarterly revenue was up 40.2% on a year-over-year basis. During the same period last year, the business posted $0.08 earnings per share. Research analysts anticipate that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.